Adenocarcinoma Lung Cancer
Find comprehensive information on Adenocarcinoma Lung Cancer, including Lung Adenocarcinoma and Pulmonary Adenocarcinoma. This resource covers diagnosis, staging, treatment, and prognosis. Learn about relevant healthcare, clinical documentation, and medical coding terms for accurate and efficient medical record keeping. Explore details related to Adenocarcinoma of the Lung for improved patient care and optimized clinical workflows.
A type of non-small cell lung cancer originating in the mucus-producing glands.
Persistent cough, shortness of breath, chest pain, fatigue, weight loss, hoarseness.
Diagnosed in hospitals or cancer centers using imaging, biopsy, and pathology tests.
ICD-10 Code Families
Complete code families applicable to C34.90
When to use each related code
| Description | When to use |
|---|---|
| Most common type of lung cancer. Starts in mucus-producing glands. | Use for malignant tumors originating in glandular cells of the lung. Specify subtype if known (e.g., acinar, papillary). |
| Second most common type of lung cancer. Linked to smoking. | Use for malignant tumors of the lung originating from squamous cells. Often centrally located. Consider subtype (e.g., keratinizing). |
| Aggressive, fast-growing lung cancer. Often occurs in smokers. | Use for poorly differentiated neuroendocrine lung carcinomas. Rapid growth and early metastasis are common features. |
Best-practice checklist
- ✓Adenocarcinoma lung cancer: Document TNM stage (AJCC 8th ed.)
- ✓Lung adenocarcinoma: Histological subtype and differentiation grade
- ✓Pulmonary adenocarcinoma: Record primary tumor location and size
- ✓Adenocarcinoma lung: Note evidence of metastasis (sites involved)
- ✓Lung cancer: Specify if biopsy/cytology confirms diagnosis
Common pitfalls to avoid
Insufficient documentation of histological subtype (e.g., acinar, papillary) may lead to inaccurate coding and reimbursement.
Distinguishing primary lung adenocarcinoma from metastatic adenocarcinoma requires careful review for correct site and laterality coding.
Incomplete staging information (TNM) impacts accurate code assignment and quality reporting, affecting treatment planning and resource allocation.
Best-practice tips
- 01Accurate ICD-10 coding (C34.-) for Adenocarcinoma Lung Cancer ensures proper reimbursement.
- 02Thorough clinical documentation specifying subtype and stage improves CDI and patient care.
- 03Timely pathology reports with biomarkers (EGFR, ALK) guide treatment and optimize outcomes.
- 04Regular follow-up and adherence to treatment protocols improve prognosis for lung adenocarcinoma.
- 05Multidisciplinary team approach (MDT) enhances communication and patient management for lung cancer.
Step-by-step checklist
- 1
Confirm histology report: Adenocarcinoma, ICD-10 C34.x
- 2
Stage using TNM, document size/location for accurate coding
- 3
Check EGFR, ALK, ROS1 mutation status for targeted therapy
- 4
Assess PD-L1 expression for immunotherapy eligibility
- 5
Review patient symptoms/performance status for treatment plan
Ready-to-paste narrative
Patient presents with complaints consistent with possible lung adenocarcinoma. Symptoms include persistent cough, hemoptysis, dyspnea, chest pain, and unexplained weight loss. The patient reports a history of smoking and occupational exposure to asbestos. Physical examination reveals decreased breath sounds and dullness to percussion in the right upper lobe. Imaging studies, including chest x-ray and CT scan of the chest, demonstrate a suspicious pulmonary nodule with characteristics suggestive of malignancy. A bronchoscopy with biopsy was performed and subsequent histopathological analysis confirmed the diagnosis of adenocarcinoma of the lung. Staging workup, including PET scan and bone scan, is underway to determine the extent of disease. The patient's case was discussed at the multidisciplinary tumor board, and a treatment plan, encompassing targeted therapy options for non-small cell lung cancer, is being formulated. Differential diagnosis included pneumonia, bronchitis, and other pulmonary malignancies such as squamous cell carcinoma and large cell carcinoma. ICD-10 code C34.90, malignant neoplasm of unspecified part of bronchus or lung, is assigned pending further staging. CPT codes for the diagnostic procedures performed have been documented. Patient education regarding lung cancer treatment options, including chemotherapy, radiation therapy, immunotherapy, and palliative care, was provided. Follow-up appointment scheduled to discuss treatment plan and prognosis in detail.
Common questions and answers
What are the key differentiating factors in the differential diagnosis of adenocarcinoma lung cancer versus squamous cell carcinoma of the lung, considering both clinical presentation and histopathological features?+
Differentiating adenocarcinoma from squamous cell carcinoma is crucial for treatment planning. Clinically, adenocarcinoma often presents with peripheral lung nodules and less frequent hemoptysis compared to squamous cell carcinoma, which is more centrally located and often associated with cavitation and hemoptysis. Histopathologically, adenocarcinoma demonstrates glandular differentiation with mucin production, while squamous cell carcinoma exhibits keratinization and intercellular bridges. Immunohistochemistry can further aid in diagnosis, with adenocarcinoma often staining positive for TTF-1 and napsin A, while squamous cell carcinoma may express p40 and CK5/6. Consider implementing immunohistochemical staining in challenging cases to improve diagnostic accuracy. Explore how molecular testing can inform targeted therapy selection based on specific driver mutations present in adenocarcinoma.
How can I accurately stage adenocarcinoma of the lung using the latest TNM staging system (8th edition) and what are the implications for treatment decisions based on stage?+
Accurate staging of lung adenocarcinoma using the 8th edition TNM system requires careful assessment of tumor size (T), nodal involvement (N), and distant metastasis (M) using imaging modalities like CT, PET, and sometimes endobronchial ultrasound or mediastinoscopy. The T descriptor considers tumor size, invasion into adjacent structures, and pleural involvement. Nodal status assesses regional lymph node involvement, while M descriptor denotes the presence or absence of distant metastases. Treatment decisions are heavily influenced by stage. Early-stage (I-II) disease may be amenable to surgical resection, while locally advanced (III) disease may require a combination of chemotherapy, radiation, and sometimes surgery. Advanced (IV) disease necessitates systemic therapies like targeted therapy or immunotherapy, depending on the molecular profile. Learn more about the specific TNM descriptors and their impact on prognosis and treatment algorithms. Consider incorporating minimally invasive staging techniques for improved patient outcomes.
What are the recommended molecular tests for patients newly diagnosed with lung adenocarcinoma and how do these results guide targeted therapy selection in clinical practice?+
Molecular testing for EGFR mutations, ALK rearrangements, ROS1 rearrangements, BRAF mutations, MET exon 14 skipping mutations, RET rearrangements, KRAS mutations, NTRK fusions, and PD-L1 expression is recommended for all patients newly diagnosed with lung adenocarcinoma. These tests guide targeted therapy selection, as specific inhibitors are available for each of these molecular alterations. For instance, patients with EGFR mutations may benefit from EGFR tyrosine kinase inhibitors, while those with ALK rearrangements are candidates for ALK inhibitors. PD-L1 expression levels can inform immunotherapy decisions. Explore how next-generation sequencing (NGS) can efficiently assess multiple genes simultaneously. Ensure timely molecular testing to facilitate prompt initiation of targeted therapy and optimize patient outcomes.
Clinical accuracy: This information is provided for documentation and coding guidance and should not replace professional medical judgment.
Coding standard: ICD-10-CM, current FY guidelines.